In the multivariable analysis, the 48 patients with tumor diameters that maintained a < 20% increase from baseline had significantly reduced hazards of death (HR = 0.15, P = 0.01) after adjusting for age, combined surgery, KRAS status, cancer type, MMR, treatment course and cancer differentiation. This evidence concerns the gene MRC1 and cancer.